Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 2)

Inclusion Criteria: * Male or female subjects must be greater than or equal to 18 years of age * Subjects must have a diagnosis of Systemic Sclerosis * Subjects must have a diagnosis or history of Raynaud's Phenomenon * Subjects must have a minimum of 10 symptomatic Raynaud's Phenomenon attacks * Female subjects of childbearing potential and male subjects must agree to use contraception for the duration of the study * Subjects must be willing and able to comply with the study requirements and give informed consent for participation in the study Exclusion Criteria: * Female subjects who are pregnant or breastfeeding * Subjects with systolic blood pressure \<85 mmHg * Subjects with an estimated glomerular filtration rate \<30 mL/min/1.73 m2 * Subjects with Child-Pugh Class B or Class C liver disease or an alanine aminotransferase and/or aspartate aminotransferase value \>3 × the upper limit of normal at screening. * Subjects with gangrene, digital ulcer infection, or requirement of cervical or digital sympathectomy * Subjects with intractable diarrhea or vomiting * Subjects with a risk of clinically significant bleeding events including those with coagulation or platelet disorders * Subjects with a history of major trauma or hemorrhage * Subjects with clinically significant chronic intermittent bleeding such as active gastric antral vascular ectasia or active peptic ulcer disease * Subjects who have had any cerebrovascular events * Subjects with a history of myocardial infarction or unstable angina within 6 months of screening * Subjects with acute or chronic congestive heart failure * Subjects with a history of life-threatening cardiac arrhythmias * Subjects with a history of hemodynamically significant aortic or mitral valve disease * Subjects with more than mild restrictive or congestive cardiomyopathy uncontrolled by medication or implanted device. * Subjects with known pulmonary hypertension, pulmonary arterial hypertension, or pulmonary veno-occlusive disease * Subjects with a history of significant restrictive lung disease defined as forced vital capacity \<45% predicted and diffusing capacity of the lungs for carbon monoxide \<40% predicted (uncorrected for hemoglobin). * Subjects with a history of cervical or digital sympathectomy * Subjects with scleroderma renal crisis * Subjects with a concomitant life-threatening disease with a life expectancy \<12 months * Subjects who have a clinically significant disorder, that in the opinion of the Investigator, could contraindicate the administration of study drug, affect compliance, interfere with study evaluations, or confound the interpretation of study results * Subjects who have taken or are currently taking any parenteral, inhaled, or oral prostacyclin or prostacyclin receptor agonists * Subjects must not initiate dosing of oral, topical, or intravenous (IV) vasodilators or if currently receiving any vasodilator must have been stably medicated * Subjects with any history of acetaminophen intolerability * Subjects with any malignancy that requires treatment during the study period, that has required treatment within 1 year of screening, or that is currently not in remission. * Subjects who have used any investigational medication or device for any indication within 30 days or 5 half-lives (whichever is longer)